Stenham Asset Management’s recent acquisition of Guernsey-based hedge fund managers Montier Partners reflects a wider trend involving the consolidation of niche firms within larger organisations, according to Andrew Boyce, corporate partner at Channel Islands law firm Carey Olsen. “Although the trend is not limited to Guernsey, it is becoming increasingly
Palamon Capital Partners, a European mid-market private equity firm, has acquired a majority stake in Eneas Energy in a transaction valued at NOK375m. Eneas is a supplier of corporate energy services in the Nordic region, generating revenue approaching NOK700m during 2010. It provides a range of services aimed at reducing
Inflexion Private Equity, a mid market private equity investor, has held the first and final close of its 2010 Buyout Fund with commitments of GBP375m. The fund was more than twice oversubscribed and fundraising was completed between June and the end of September. The fund includes investment from a
Vision Capital has opened its New York office and completed of its acquisition of the assets of Terphane, a manufacturer of speciality polyester films, from a syndicate of financial investors. Vision Capital has invested in the Americas since 2004 and has three existing portfolio companies in the region, which are
Yorkville Advisors, the US-based investment manager to an alternative investment fund, has entered into a GBP20m standby equity distribution agreement on behalf of one of its funds with AIM listed Xcite Energy. Xcite Energy is an exploration and development company focused on heavy oil resources in the North Sea. Xcite
HarbourVest Global Private Equity, a closed-end investment company listed on Euronext Amsterdam and the Specialist Fund Market of the London Stock Exchange, has reported an increase in economic net asset value of 4.4 per cent over the six months ended 31 July 2010. As at 31 July 2010, HarbourVest’s economic
California based SDS Ventures is launching a biotechnology fund in October 2010. The fund is raising up to USD75m with a focus on oncology biotechnology companies with at least one phase three drug in the pipeline. SDS Ventures has already identified a California based prospective portfolio company and is currently
The Blackstone Group and Patria, a Brazilian alternative asset manager, have formed a partnership in which Blackstone would purchase a 40 per cent stake in Patria and the two firms would agree to cooperate in building their businesses in Brazil and throughout South America. Stephen A. Schwarzman, chairman and chief
Protox Therapeutics, a developer of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, has entered into an investment agreement with private equity firm Warburg Pincus. Under the agreement, Warburg Pincus Private Equity X and Warburg Pincus X Partners have committed to invest up to
Rypple, a provider of social software for workplace feedback, has raised USD7m in financing led by Bridgescale Partners. Howard Gwin (pictured), a Bridgescale partner and former executive vice president at PeopleSoft, and Roger Martin, Dean of the Rotman School of Management, will join the company’s board of directors. Additional investors
12 November, 2026 – 5:00 pm
12 November, 2026 – 8:00 am
12 February, 2026 – 8:00 am
12 February, 2026 – 5:00 pm
